Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
daclatasvir (daklinza) (1 trial)
l-epigallocatechin (1 trial)
natural anti-hemolytic (1 trial)
ribavirin (virazole) (2 trials)
sofosbuvir (sovaldi) (2 trials)
Hepatitis C (Phase 3)
Trials (2 total)
Trial APIs (5 total)